This fall and winter, Ontario, Quebec and Nunavut will offer the newer monoclonal antibody nirsevimab — approved by Health ...

All palivizumab doses were given during or within 30 days of the RSV season, November 1 through April 1. During the pre-2014 guideline period, the rate of RSV hospitalizations in children younger ...

Respiratory Syncytial Virus (RSV) remains a critical health issue globally, particularly affecting vulnerable populations ...

RSV and the common cold both cause symptoms of viral infection. Coughing tends to be more severe in RSV. Learn how RSV vs.

For years, that antibody was palivizumab, which had to be given every month throughout the RSV season to maintain immunity. This fall and winter, Ontario, Quebec and Nunavut will offer the newer ...

AI (in this case, ChatGPT) is an amazing tool for science and medical writers. But it's not perfect. It sometimes makes ...

AZ's Synagis (palivizumab) is currently the only approved drug in Europe to provide passive prophylaxis against RSV, but has to be given monthly, whereas nirsevimab can provide protection ...